TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29318418

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (US) at continuous mode, 1-MHz frequency, and 1.5-W/cm2 intensity for 10 sessions
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (unaffected cervical NR)
Number of subjects: 32
Study: 24432969

Group type: EXPERIMENTAL
Intervention: Video game performance
Number of subjects: 29

Group type: COMPARATOR
Intervention: Traditional surgical skills
Number of subjects: 29

Group type: COMPARATOR
Intervention: Laparoscopic skills
Number of subjects: 29
Study: 22609300

Group type: EXPERIMENTAL
Intervention: Aquatic exercise training (3 times a week, 60 minutes per session for 8 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 32
Study: 20423986

Group type: EXPERIMENTAL
Intervention: Ghrelin (50 microg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18698280

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 15924594

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily (continuous)
Number of subjects: 2156

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg on-demand
Number of subjects: 2156

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice-daily (continuous)
Number of subjects: 2156

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily (during the 4-week symptom control phase)
Number of subjects: 2156
Study: 12562742

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Risperidone (post hoc analysis excluding carbamazepine-treated patients)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo (post hoc analysis excluding carbamazepine-treated patients)
Number of subjects: 151
Study: 10650568

Group type: EXPERIMENTAL
Intervention: Sucralfate (2 g/tid p.o. before meals)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 120
Study: 7745965

Group type: EXPERIMENTAL
Intervention: Hepatectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no hepatectomy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepatectomy Group A (AKBR maintained at 0.7 or more)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepatectomy Group B (AKBR decreased to below 0.7)
Number of subjects: 0
Study: 1967882

Group type: EXPERIMENTAL
Intervention: 1% hydrogen peroxide in a stabilized lipid cream applied for 2 min before UVA exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1% hydrogen peroxide pretreatment before each UVA irradiation during maintenance exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: UVA exposure alone after finishing hydrogen peroxide pretreatment
Number of subjects: 0
Study: 6160324

Group type: EXPERIMENTAL
Intervention: Intravenous pindolol (0.4 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral pindolol (5 mg, t.i.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31784852

Group type: EXPERIMENTAL
Intervention: HPI (n=25)
Number of subjects: 99

Group type: COMPARATOR
Intervention: CTRL (n=24)
Number of subjects: 99

Group type: COMPARATOR
Intervention: hCTRL (n=50)
Number of subjects: 99
Study: 30680547

Group type: EXPERIMENTAL
Intervention: Vitamin B12-fortified toothpaste (100 µg cyanocobalamin/g)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 92
Study: 28697211

Group type: EXPERIMENTAL
Intervention: Cement-retained (CR) crowns
Number of subjects: 51

Group type: COMPARATOR
Intervention: Screw-retained (SR) crowns
Number of subjects: 51
Study: 25887747

Group type: EXPERIMENTAL
Intervention: GP-led telephone triage
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Nurse-led telephone triage
Number of subjects: 44

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 44
Study: 23318812

Group type: EXPERIMENTAL
Intervention: Bupivacaine (30 ml bolus at 2.5 mg/ml followed by continuous infusion at 5 ml/h for 48 hours)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (isotonic saline, same administration as bupivacaine)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 50
Study: 21111685

Group type: EXPERIMENTAL
Intervention: Acupuncture (8 sessions over 4 weeks)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Prednisolone 20 mg daily for 2 weeks followed by 10 mg daily for 2 weeks (n = 39)
Number of subjects: 77
Study: 19505986

Group type: EXPERIMENTAL
Intervention: Long-acting β-agonist (LABA) with mandatory inhaled corticosteroid (ICS) therapy
Number of subjects: 60954
Study: 16760520

Group type: EXPERIMENTAL
Intervention: Rifaximin 200 mg three times a day
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg two times a day
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo three times a day
Number of subjects: 399
Study: 15065973

Group type: EXPERIMENTAL
Intervention: Feedback with varying specificity
Number of subjects: 0
Study: 11375342

Group type: EXPERIMENTAL
Intervention: KPT‐S
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: KPT‐P
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: KPT‐S and KPT‐P
Number of subjects: 31
Study: 9163658

Group type: EXPERIMENTAL
Intervention: Sparfloxacin (SPX), 400 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ciprofloxacin (CPX), 500 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sparfloxacin (SPX)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ciprofloxacin (CPX)
Number of subjects: 31
Study: 8142159

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (96 mg IV bolus, followed by 96 mg orally for 3 days, then tapered over 10 days)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No dexamethasone therapy (control group)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone
Number of subjects: 57
Study: 3061316

Group type: COMPARATOR
Intervention: Soya substitute feeding (cows' milk deliberately withheld)
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Breast feeding
Number of subjects: 487

Group type: COMPARATOR
Intervention: Environmental factors (smoking, social class, month of birth, dampness, mould, coal fires)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Eczema
Number of subjects: 487

Group type: COMPARATOR
Intervention: IgE and IgG4 antibodies
Number of subjects: 487
Study: 30292588

Group type: EXPERIMENTAL
Intervention: Biodegradable Intramedullary Nailing (BIN) using polylactide-co-glycolide (PLGA) nails (Activa IM-Nail™, Bioretec Ltd., Finland)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Titanium Intramedullary Nailing (ESIN) using titanium nails (TEN®, SynthesDePuy Ltd., USA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Titanium Intramedullary Nailing (ESIN)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Biodegradable Intramedullary Nailing (BIN)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 35
Study: 28851403

Group type: EXPERIMENTAL
Intervention: mrTRG-directed management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional management according to baseline MRI
Number of subjects: 0
Study: 26237806

Group type: EXPERIMENTAL
Intervention: Herbal- and peloidotherapy as a combination treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upgraded combination scheme for the treatment of chronic cystitis
Number of subjects: 0
Study: 23011683

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) therapy, 20 min/day, 5 days/week for 12 months
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (observation alone)
Number of subjects: 149
Study: 21963122

Group type: EXPERIMENTAL
Intervention: Scheduled Telephone Intervention (STI)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 433
Study: 18602725

Group type: EXPERIMENTAL
Intervention: Sublingual administration of 10 million IU of IFNalpha
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16809727

Group type: EXPERIMENTAL
Intervention: Trastuzumab added concurrently, sequentially, or not at all as adjuvant therapy
Number of subjects: 2535

Group type: COMPARATOR
Intervention: Local laboratory testing
Number of subjects: 2535

Group type: COMPARATOR
Intervention: Reference laboratory testing
Number of subjects: 2535
Study: 15323468

Group type: EXPERIMENTAL
Intervention: Surgical intervention for spinal metastatic disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of surgical intervention and radiotherapy
Number of subjects: 0
Study: 11064610

Group type: EXPERIMENTAL
Intervention: Alfentanil and propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl and propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sufentanil and propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alfentanil, fentanyl, and sufentanil
Number of subjects: 60
Study: 8646692

Group type: EXPERIMENTAL
Intervention: Treatment variables (not specified)
Number of subjects: 2105
Study: 1484382

Group type: EXPERIMENTAL
Intervention: Self-management strategy
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Positive reinforcement strategy
Number of subjects: 159

Group type: COMPARATOR
Intervention: No maintenance strategy
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Both strategies (self-management and positive reinforcement)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Neither strategy
Number of subjects: 159
Study: 6088368

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine twice daily
Number of subjects: 197

Group type: COMPARATOR
Intervention: 200 mg cimetidine three times a day and 400 mg at night
Number of subjects: 197
Study: 30039902

Group type: EXPERIMENTAL
Intervention: EPG therapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: EPG-informed conventional therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 27
Study: 30332430

Group type: EXPERIMENTAL
Intervention: 150 min/week of aerobic exercise (low-dose) for six months
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 300 min/week of aerobic exercise (high-dose) for six months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 23
Study: 27258504

Group type: EXPERIMENTAL
Intervention: Ticagrelor loading dose of 360 mg
Number of subjects: 250

Group type: COMPARATOR
Intervention: Ticagrelor loading dose of 180 mg (conventional)
Number of subjects: 250
Study: 24621269

Group type: EXPERIMENTAL
Intervention: Medicinal bath with traditional Chinese herb formula
Number of subjects: 80

Group type: COMPARATOR
Intervention: Perfume water bath (placebo)
Number of subjects: 80
Study: 21872485

Group type: EXPERIMENTAL
Intervention: Triterpene ointment (OG-S10) applied at 100 mg/cm² for 14 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Moist wound dressing (Mepilex)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Triterpene ointment (OG-S10)
Number of subjects: 24
Study: 19932542

Group type: EXPERIMENTAL
Intervention: Adalimumab, 24 mg/m², every 14 days for 16 weeks (total, 9 doses)
Number of subjects: 10
Study: 17106276

Group type: EXPERIMENTAL
Intervention: PEG + RBV
Number of subjects: 95

Group type: COMPARATOR
Intervention: IFN + RBV
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 95
Study: 15909266

Group type: EXPERIMENTAL
Intervention: Artesunate-clindamycin (2 mg/kg artesunate and 7 mg/kg clindamycin per dose, twice daily for 3 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Quinine-clindamycin (15 mg/kg quinine and 7 mg/kg clindamycin per dose, twice daily for 3 days)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Artesunate-clindamycin
Number of subjects: 100
Study: 12483054

Group type: EXPERIMENTAL
Intervention: 5% albumin prime
Number of subjects: 86

Group type: COMPARATOR
Intervention: Crystalloid prime
Number of subjects: 86
Study: 9578170

Group type: EXPERIMENTAL
Intervention: Ceftazidime 320 mg/kg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceftazidime 150 mg/kg/day
Number of subjects: 0
Study: 7666094

Group type: EXPERIMENTAL
Intervention: Interferon (2 mU/m2) subcutaneously three times per week
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control (no maintenance)
Number of subjects: 176
Study: 2527543

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 0
Study: 30208372

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation targeting the left dorsal‐lateral prefrontal cortex
Number of subjects: 0
Study: 28338849

Group type: EXPERIMENTAL
Intervention: lifestyle Matters intervention (weekly group sessions over 4 months and one to one sessions)
Number of subjects: 288

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 288
Study: 25930952

Group type: EXPERIMENTAL
Intervention: CBT4CBT (computerized cognitive behavioral therapy)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard treatment (methadone maintenance treatment alone)
Number of subjects: 101
Study: 23305089

Group type: EXPERIMENTAL
Intervention: 0-back test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2-back test
Number of subjects: 0
Study: 22027666

Group type: EXPERIMENTAL
Intervention: Cytoflavin
Number of subjects: 60
Study: 19910808

Group type: EXPERIMENTAL
Intervention: CoreControl Rapid Thermal Exchange (RTX) at 15 degrees C
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 15 degrees C standard refrigerant gel pack (P)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (C) - nothing at all
Number of subjects: 10
Study: 16864668

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiography
Number of subjects: 352

Group type: COMPARATOR
Intervention: Duplex US
Number of subjects: 352
Study: 12641626

Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 157

Group type: COMPARATOR
Intervention: NHP
Number of subjects: 157
Study: 10730020

Group type: EXPERIMENTAL
Intervention: Pharmacist‐directed lipid management program
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study: 8957971

Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional open repair
Number of subjects: 20
Study: 1539751

Group type: EXPERIMENTAL
Intervention: Chloroquine 600 mg/week
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Chloroquine 300 mg/week
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Chloroquine 600 mg (post-treatment)
Number of subjects: 3
Study: 3516299

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 60
Study: 29688139

Group type: EXPERIMENTAL
Intervention: Community health workers (CHWs) providing HIV and health education, counseling, social support, and facilitating communication with HIV clinics.
Number of subjects: 1799

Group type: COMPARATOR
Intervention: Control group (no CHW intervention).
Number of subjects: 1799
Study: 27753558

Group type: EXPERIMENTAL
Intervention: Fitbit pedometers
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 107
Study: 24778171

Group type: EXPERIMENTAL
Intervention: Water immersion (WI)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Water immersion (WI) and Lower body negative pressure (LBNP)
Number of subjects: 17
Study: 22555575

Group type: EXPERIMENTAL
Intervention: Parent vessel occlusion (PVO) for anterior circulation aneurysms presenting with mass effect (n = 11)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Parent vessel occlusion (PVO) for dissecting-type VB aneurysms presenting with subarachnoid hemorrhage (n = 6)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Parent vessel occlusion (PVO) for VB aneurysms presenting with mass effect (n = 7)
Number of subjects: 28
Study: 20102926

Group type: EXPERIMENTAL
Intervention: Exercise training (3 sessions/week, 60 minutes each, at anaerobic threshold intensity)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (medical treatment only)
Number of subjects: 23
Study: 18970937

Group type: EXPERIMENTAL
Intervention: Open pyloromyotomy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Laparoscopic pyloromyotomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 200
Study: 15967846

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg PO BID
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg PO TID
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg PO BID plus Captopril 50 mg PO TID
Number of subjects: 610

Group type: COMPARATOR
Intervention: Baseline echocardiographic measures
Number of subjects: 610
Study: 11900261

Group type: EXPERIMENTAL
Intervention: Group A - 6-month supervised outpatient exercise program (3 weekly sessions of aerobic and strengthening training on non-dialysis days)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group B - 6-month exercise program during hemodialysis
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group C - unsupervised moderate exercise program at home
Number of subjects: 48

Group type: COMPARATOR
Intervention: Group D - patient control group (no exercise intervention)
Number of subjects: 48
Study: 9918607

Group type: EXPERIMENTAL
Intervention: Humidified CO2 insufflation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard CO2 insufflation (Control)
Number of subjects: 40
Study: 7675587

Group type: EXPERIMENTAL
Intervention: Lifestyle exercise materials
Number of subjects: 14

Group type: COMPARATOR
Intervention: Structured exercise materials
Number of subjects: 14
Study: 2119323

Group type: EXPERIMENTAL
Intervention: Tolrestat 200 mg once daily
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 7428365

Group type: EXPERIMENTAL
Intervention: 1 mg vaginal suppository of 15-methyl prostaglandin F2 alpha-methyl ester for Group 1 (9-12 weeks pregnant)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: 1.5 mg vaginal suppository of 15-methyl prostaglandin F2 alpha-methyl ester for Group 2 (13-14 weeks pregnant)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Both treatment groups (1 mg and 1.5 mg)
Number of subjects: 489
Study: 30453788

Group type: EXPERIMENTAL
Intervention: 12-h acetylcysteine regimen (200 mg/kg over 4 h, 50 mg/kg over 8 h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 20-h acetylcysteine regimen (200 mg/kg over 4 h, 100 mg/kg over 16 h)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 12-h acetylcysteine regimen
Number of subjects: 40

Group type: COMPARATOR
Intervention: 20-h acetylcysteine regimen
Number of subjects: 40
Study: 28493646

Group type: EXPERIMENTAL
Intervention: No Objective Testing Rule (NOTR)
Number of subjects: 282

Group type: COMPARATOR
Intervention: HEART Pathway
Number of subjects: 282
Study: 26887209

Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES) of Zusanli (ST 36)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (comprehensive treatment only)
Number of subjects: 116
Study: 23063327

Group type: EXPERIMENTAL
Intervention: Memantine (10 mg/day for the first week, and 20 mg/day for the rest of the trial)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 42
Study: 21515866

Group type: EXPERIMENTAL
Intervention: Conivaptan hydrochloride 20 mg once daily
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Conivaptan hydrochloride 20 mg twice daily
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 18246390

Group type: EXPERIMENTAL
Intervention: Selective IOPTH-guided PA (group B)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Elective PA without IOPTH guidance (group A)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 340
Study: 16552014

Group type: EXPERIMENTAL
Intervention: 40 microg/kg of recombinant activated factor VII (rFVIIa)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 80 microg/kg of recombinant activated factor VII (rFVIIa)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 160 microg/kg of recombinant activated factor VII (rFVIIa)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15327694

Group type: EXPERIMENTAL
Intervention: Educational intervention (audit and feedback mechanism combined with optional Continuing Medical Education workshop)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 0
Study: 10938172

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 1957

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 1957

Group type: COMPARATOR
Intervention: TIMI risk score
Number of subjects: 1957
Study: 9359026

Group type: EXPERIMENTAL
Intervention: Samarium 153Sm lexidronam 1 mCi/kg (37 MBq/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8471145

Group type: EXPERIMENTAL
Intervention: Granuflex 'E' (n = 49)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Bactigras (n = 49)
Number of subjects: 98
Study: 3804905

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus benzylpenicillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard empirical regimen of netilmicin and piperacillin
Number of subjects: 0
Study: 29423372

Group type: EXPERIMENTAL
Intervention: Strengthened inhalation therapy for asthma
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 15
Study: 26774179

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d for the first 15 days, 40 mg/d thereafter; n = 69)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo (n = 78)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d for the first 15 days, 40 mg/d thereafter)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d)
Number of subjects: 158
Study: 25274783

Group type: EXPERIMENTAL
Intervention: Proximal opening wedge osteotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proximal chevron osteotomy
Number of subjects: 0